What to know about the CEO caught embracing an employee on the jumbtron at a Coldplay concert
The snippet of video set the internet alight, fueling a wave of memes and drawing attention to the erosion of privacy in public spaces.
Here are some things to know:
What happened at the concert
During the concert on Wednesday at Gillette Stadium in Foxborough, Massachusetts, lead singer Chris Martin asked the cameras to scan the crowd for his 'Jumbotron Song,' when he sings a few lines about the people the camera lands on.
A man wearing a birthday sash was up first. Two people in banana costumes were highlighted.
But in between, something unexpected happened. For several seconds, a couple was shown on the big screen. They were cuddling and smiling, his arms wrapped around her, as she leaned back into him.
When they saw themselves on the big screen, her jaw dropped, her hands flew to her face and she spun away from the camera. He ducked out of the frame, as did she.
'Either they're having an affair or they're just very shy,' Martin joked.
It didn't end there.
Who was involved
After the video went viral, the internet got to work.
Online sleuths rapidly figured out that the man was Andy Byron, chief executive officer, while she was Kristin Cabot, the chief people officer — in other words, the head of human resources.
Astronomer, based in New York, provides big companies with a platform that helps them organize their data.
The company at first said little about the incident. In response to an initial inquiry from The Associated Press, Astronomer's spokesman said only that a statement attributed to Byron that circulated online immediately after the incident was a 'fake from a clearly labeled parody account.'
The company later confirmed the identities of the couple in a statement to AP.
What happened to the CEO
In the hours after the video went viral, Byron's name was at one point the most searched term on Google.
Astronomer eventually addressed the situation, announcing in a LinkedIn post that Byron had been placed on leave and that the board of directors had launched a formal investigation.
The company said a day later that Byron had resigned, and that its cofounder and chief product officer, Pete DeJoy, was tapped as interim CEO while it searches for Byron's successor.
'Astronomer is committed to the values and culture that have guided us since our founding. Our leaders are expected to set the standard in both conduct and accountability, and recently, that standard was not met,' the company said in its post on LinkedIn.
Most concert venues warn attendees that they can be film
ed
It's easy to miss, but most concert venues have signs informing the audience that they could be filmed during the event. Look for them on the walls when you arrive and around the bar areas or toilets. It's common practice especially when bands like to use performances for music videos or concert films.
The venue in this case, Gillette Stadium in Foxborough, also has a privacy policy online which states: 'When you visit our location or attend or participate in an event at our location, we may capture your image, voice and/or likeness, including through the use of CCTV cameras and/or when we film or photograph you in a public location.'
Once captured, a moment can be shared widely
In the internet age, such videos — or ones taken on someone's smartphone — can quickly zip around the world.
This video rocketed around social media, as people speculated about why the couple dodged the camera.
Empathy for the pair and their families was mixed with plenty of snarky commentary and countless memes, with the fake statement from the chief executive generating a lot of additional vitriol. And news reports said that Byron's LinkedIn account was disabled after it was flooded by a wave of comments.
'It's a little bit unsettling how easily we can be identified with biometrics, how our faces are online, how social media can track us — and how the internet has gone from being a place of interaction, to a gigantic surveillance system," said Mary Angela Bock, an associate professor in the University of Texas at Austin's School of Journalism and Media. "We are being surveilled by our social media. They're tracking us in exchange for entertaining us.'
_____
AP Business Writer Wyatte Grantham-Philips contributed to this report from New York.
Kelvin Chan And Hilary Fox, The Associated Press
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
BD Announces First Pharma-Sponsored Clinical Trial Using BD Libertas™ Wearable Injector Technology for Biologic Drugs
FRANKLIN LAKES, N.J., July 23, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announces the first pharma-sponsored combination product clinical trial using the BD Libertas™ Wearable Injector for subcutaneous delivery of complex biologics. The selection of BD Libertas™ Wearable Injector for this pharma-sponsored trial follows successful outcomes from more than 50 BD-conducted pre-clinical and clinical studies, including a device clinical study demonstrating excellent performance with 100% of study participants stating they would likely use the BD Libertas™ Wearable Injector if prescribedi,ii. The pharma-sponsored combination product clinical trial represents a significant advancement in accelerating innovation in drug-device combination products that provide greater flexibility for patients, including potential conversion from infused medications that require patients to travel to a hospital or clinic to more convenient patient care in various settings, including self-injection at home. "This trial demonstrates BD's commitment to helping pharma companies by advancing large-volume injection science, ensuring therapies are accessible and patient friendly by offering more efficient and convenient options for biologics," said Patrick Jeukenne, worldwide president of BD Pharmaceutical Systems. "BD's enhanced testing capabilities acquired through ZebraSci and the proven capabilities of the BD Libertas™ Wearable Injector technology further position BD as an innovative leader in drug delivery." The BD Libertas™ Wearable Injector is an innovative, prefilled, patient ready-to-use drug delivery systemiii designed to enable delivery of complex biologics via subcutaneous injection. The biologics market is expected to grow to more than $670 billioniv by 2030 and for pharmaceutical companies developing these complex drugs, the BD Libertas™ Wearable Injector offers a customizable, patient-centric solution. The BD Libertas™ Wearable Injector: Supports delivery of high-viscosity biologics (up to 50 centipoise), enabling a wide range of subcutaneous therapies Is offered in 2 to 5 mL and 5 to 10 mL configurations providing flexibility for diverse therapeutic requirements Features a fully mechanical, patient ready-to-use design with a simple "peel, stick and click" mechanism, requiring no end-user filling or assemblyiii BD's ongoing validations of fill-finish and final assembly processes with multiple Contract Manufacturing Organizations (CMOs) enable the company to support pharmaceutical partners from development through commercial-scale production. For more information about how BD Libertas™ Wearable Injector is enabling biologic therapy delivery, visit About BD Libertas™ Wearable InjectorBD Libertas™ Wearable Injector is a product in development; some statements are forward looking and are subject to a variety of risks and uncertainties. BD Libertas™ Wearable Injector is a device component intended for drug-device combination products and not subject to FDA 510(k) clearance or separate EU CE mark certification. About BD BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit or connect with us on LinkedIn at X (formerly Twitter) @BDandCo or Instagram @becton_dickinson. Contacts: Media: Investors: Fallon McLoughlin Adam Reiffe BD Corporate Communications BD Investor Relations 201.258.0361 201.847.6927 i Early feasibility clinical study of investigational BD Libertas™ Wearable Injector (WI) evaluated 5ml, non- Newtonian ~8cP subcutaneous placebo injections in 52 healthy adult subjects for functionality, tissue effects, subject tolerability (100mm Visual Analog Scale (VAS)) and acceptability (questionnaires with 5-point Likert or yes /no responses). Tissue effects were measured from WI removal post-injection through 24 hours with calipers (wheals) or graded on a 5-point scale (erythema, bleeding) from 0-none to 4-severe, significant, respectively. Where tissue effects were observed, the majority (>50%) were resolved within 60 minutes and all within 24 hours. Subject pain (100mm VAS) peaked mid-injection (mean 9.1mm, SD 13.4) and rapidly resolved within 30 minutes (mean 0 .4mm, SD 2.6). Subjects found acceptable (Likert agree + strongly agree or yes responses) their peak pain (≥90.2%), injection site appearance (≥92.2% ).ii Woodley, W. D. et al. Clinical Evaluation of an Investigational 5ml Wearable Injector in Healthy Human Subjects. Clin Transl Sci. 2021 May;14(3):859-869. Pharma filled and assemblediv Mordor Intelligence (2025). Biologics Market Size - Industry Report on Share, Growth Trends & Forecasts Analysis (2025 - 2030). View original content to download multimedia: SOURCE BD (Becton, Dickinson and Company) Sign in to access your portfolio


Fox News
15 minutes ago
- Fox News
'Ruthless' applauds Trump's late-night fight: 'Take it back to basics'
'Ruthless' podcast co-hosts Michael Duncan, Comfortably Smug and John Ashbrook join 'Fox & Friends' to break down the fallout from CBS parting ways with 'The Late Show' and host Stephen Colbert.


Fox News
15 minutes ago
- Fox News
'The View' host Sunny Hostin warns Colbert cancellation could lead to the 'dismantling of our Constitution'
"The View" co-host Sunny Hostin warned on Tuesday that CBS canceling Stephen Colbert's "Late Show" could be the start of the "dismantling of our Constitution." CBS announced Thursday "The Late Show" will end in May at the end of its broadcast season. Though CBS and parent company Paramount said the choice to cancel the series was "purely a financial decision," and the show was reportedly losing the network $40 million a year, many liberal commentators claim it was for political reasons. Just days before the cancellation, Colbert slammed Paramount's recent settlement with President Donald Trump over his lawsuit against "60 Minutes" as a "big fat bribe" ahead of a pending merger between Paramount and Skydance Media. Hostin and her fellow co-hosts were also skeptical of CBS' explanation for canceling Colbert's show based on the "timing" of the announcement. She pointed out that if politics were involved, then the fabric of democracy could be in jeopardy. "My concern is, if it is political, then everyone should be concerned. People on the right should be concerned. People on the left should be concerned. Because it's very clear that, if it is political, this is the dismantling of our democracy. This is the dismantling of our Constitution. Right?" Hostin said to the cheering of the studio audience. She continued, "The First Amendment is the First Amendment for a reason and that is freedom of the press, freedom of speech. Freedom to speak truth to power. If that is taken away, if the comedians are being attacked, then that means our Constitution is being dismantled… That means the very rubric of our democracy is being dismantled. And I think every single person should be really, really concerned about it." Hostin praised Sens. Elizabeth Warren, D-Mass., and Bernie Sanders, I-Vt., for speaking up on the issue and demanding answers. Several other high-profile Democrats also spoke out against canceling Colbert, whose show was openly favorable to their party while hostile to Republicans. "We must protect our Constitution and we must protect our democracy! This is bigger than just the cancellation of a television show!" Hostin exclaimed. Her co-host Joy Behar blamed Trump for Colbert's cancellation and warned "all bets are off" if comedians are taken down. "It's always been the role of the court jester to make fun of the king. That is the role of comedians. I have said on this show, I think I said it years ago, when they start coming for the comedian, all bets are off, because the king is supposed to take the hits and this guy has a skin thinner than, I don't know, than this card," Behar said, holding one up. Colbert fired back against Trump on his show Monday night after the president celebrated his show ending on Truth Social, writing, "I absolutely love that Colbert got fired. His talent was even less than his ratings. "How dare you, sir?" Colbert responded. "Would an untalented man be able to compose the following satirical witticism? Go f--- yourself."